Louis Navellier, Navellier and Associates, shares his new buy/sell stock strategy. Also Navellier provides his outlook on Apple.» Read More
Feb 18- Samsung Electronics Co Ltd has bought U.S. mobile wallet startup LoopPay, signalling its intention to launch a smartphone payments service to compete with a recent offering from rival Apple Inc.. Apple, Google, and eBay Inc's PayPal have all launched services to allow users to pay in stores via smartphones. He would not be drawn on speculation the company...
Feb 17- CVS Health on Monday warned that costs of a potent new class of cholesterol treatments and other specialty drugs in development could eclipse those of expensive new medicines and overwhelm the healthcare system "if rigid cost control mechanisms are not put in place." CVS' call for cost controls follows sharp criticism from insurers, other payers and...
Feb 17- CVS Health Corp, the second-largest U.S. pharmacy chain operator, has warned that a new class of drugs being developed to lower "bad" cholesterol could cost the U.S. healthcare system as much as $150 billion per year. The new class of cholesterol drugs called PCSK9 inhibitors could be priced in the range of $7,000- $12,000 per year, CVS said.
David Dorman, CVS Health non-executive chairman, discusses the upside of CVS's healthy sales record and the outlook on health care costs.
Feb 11- Drugstore operator Rite Aid Corp agreed to buy pharmacy benefit manager EnvisionRx for about $2 billion, looking to cut drug procurement costs as reimbursement rates fall. Rite Aid's deal comes nearly a decade after larger rival CVS Health Corp bought Caremark Rx for $21 billion, the only other example of a drug chain buying a benefits manager.
Feb 11- Drugstore operator Rite Aid Corp said it would buy pharmacy benefit manager EnvisionRx for about $2 billion, entering the business of administering health plan benefits. The deal will help Rite Aid compete better with CVS Health Corp, which bought Caremark Rx for $21 billion in 2006.. The acquisition of EnvisionRx will also give Rite Aid access to more...
Billions of consumers belong to rewards programs. These are the most worthwhile.
Recommendations from the OECD may form the basis of a deal sought by Greece with euro zone finance ministers.
Discussing Q4 earnings, Stephen Holmes, Wyndham Worldwide CEO, says the company is not terribly impacted by a strong dollar.
Meredith Adler, food and drug analyst at Barclays Capital, discusses the significance of CVS's beat on the top line. Adler still likes the stock.
Feb 10- CVS Health Corp reported a better-than-expected quarterly net revenue, boosted by growth in its Medicaid business and strength in specialty drug sales. CVS became the first national drugstore chain in the United States to take cigarettes off its shelves from Oct. 1. CVS Health has focused on developing its specialty pharmacy business, which sells drugs...
Feb 10- CVS Health Corp, the No. 2 U.S. drugstore operator, reported a better-than-expected quarterly net revenue, helped by a jump in pharmacy same-store sales and strength in its specialty pharmacy business. CVS Health has focused on developing its specialty pharmacy business, which sells drugs to treat complex diseases such as multiple sclerosis, rheumatoid...
Some of the names on the move ahead of the open.
Investors are looking at further confirmation of an improving U.S. job market with two data points that come out on Tuesday.
A Vermont gas station attendant and janitor, invested in recognizable names when he amassed an $8 million fortune, his attorney said.
Jim Cramer sees that the market is in a sweet spot for earnings. With a new landscape, he's betting that these are the hot stocks to watch.
Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.
A leading group of physicians is warning that high prices of specialty drugs is creating barriers to care for patients.
Jan 30- AbbVie Inc's chief executive said on Friday the company's new oral hepatitis C treatment Viekira Pak has the potential to capture a "meaningful share" of the U.S. market, where it is competing against Gilead Sciences. AbbVie CEO Richard Gonzalez told investors the company expects an annualized sales run rate of more than $3 billion by the end of 2015, which...
U.S. drugmaker AbbVie's revenue beat analysts' estimates for the fourth straight quarter as sales of arthritis drug Humira jumped nearly 11 percent.